Efficacy and safety of iruplinalkib (WX-0593) in ALK-positive crizotinib-resistant advanced non-small cell lung cancer patients: a single-arm, multicenter phase II study (INTELLECT)
iruplinalkib (WX-0593) 治疗 ALK 阳性克唑替尼耐药的晚期非小细胞肺癌患者的疗效和安全性:一项单臂、多中心 II 期研究 (INTELLECT)
期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-023-02738-5
Shi, Yuankai; Chen, Jianhua; Zhang, Helong; Zhang, Zhihong; Zhang, Yiping; Wang, Zhehai; Zhang, Shucai; Zhao, Jian; Liu, Chunling; Wang, Xiuwen; Zhao, Yanqiu; Hu, Changlu; Yang, Lei; Hao, Xuezhi; Wang, Lin; Liu, Yunpeng; Yu, Yan; Zhao, Jun; Wang, Mengzhao; Zhang, Liangming; Sun, Sanyuan; Hu, Yanping; Gu, Kangsheng; Hang, Xiaosheng; Shan, Jinlu; Zhang, Yu; Tan, Bangxian; Yang, Weihua; Yang, Runxiang; Si, Meimei; Geng, Huaize; Li, Hui; Kang, Xiaoyan